ASCO/ESMO Joint Session at #ASCO25 Will Highlight Key Issues in Biomarker-Driven Therapeutics dailynews.ascopubs.org/do/asco-esmo...
Looking forward to following the posts on this important topic! #oncsky @oncoalert.bsky.social
Looking forward to following the posts on this important topic! #oncsky @oncoalert.bsky.social
ASCO/ESMO Joint Session at ASCO25 Will Highlight Key Issues in Biomarker-Driven Therapeutics
The ASCO/ESMO Joint Session at the ASCO Annual Meeting will explore emerging trends and clinical implications of integrating biomarker-driven therapies into clinical care. The session will address cha...
dailynews.ascopubs.org
May 24, 2025 at 11:36 AM
ASCO/ESMO Joint Session at #ASCO25 Will Highlight Key Issues in Biomarker-Driven Therapeutics dailynews.ascopubs.org/do/asco-esmo...
Looking forward to following the posts on this important topic! #oncsky @oncoalert.bsky.social
Looking forward to following the posts on this important topic! #oncsky @oncoalert.bsky.social
AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes: Cancer Cell www.cell.com/cancer-cell/...
AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes
Arango-Argoty et al. introduce the Predictive Biomarker Modeling Framework (PBMF),
an AI-driven contrastive learning framework to identify putative predictive, rather
than prognostic, biomarkers for c...
www.cell.com
April 22, 2025 at 5:55 AM
AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes: Cancer Cell www.cell.com/cancer-cell/...
#asco25 joint @ascocancer.bsky.social @myesmo.bsky.social session on “Biomarker-driven Therapeutics: Translating Innovation into Practice” @drbonillaonc.bsky.social
June 3, 2025 at 2:35 PM
#asco25 joint @ascocancer.bsky.social @myesmo.bsky.social session on “Biomarker-driven Therapeutics: Translating Innovation into Practice” @drbonillaonc.bsky.social
New genetic findings confirm key risk factors for Long COVID, advancing precision diagnostics and treatment. Over 88% of previously identified genes were replicated, strengthening efforts to develop biomarker-driven tests and accelerate clinical trials for effective therapies.
PrecisionLife and Metrodora Foundation Announce Confirmation of Key Genetic Findings for Long COVID across Diverse Populations
www.biospace.com
February 27, 2025 at 1:44 AM
New genetic findings confirm key risk factors for Long COVID, advancing precision diagnostics and treatment. Over 88% of previously identified genes were replicated, strengthening efforts to develop biomarker-driven tests and accelerate clinical trials for effective therapies.
The TRAINER phase II study evaluates #Biomarker-driven total #Neoadjuvant therapy with bevacizumab or cetuximab for high-risk #RectalCancer, reporting complete responses and high sphincter preservation.
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
September 26, 2026 at 6:30 AM
The TRAINER phase II study evaluates #Biomarker-driven total #Neoadjuvant therapy with bevacizumab or cetuximab for high-risk #RectalCancer, reporting complete responses and high sphincter preservation.
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
📣 New preprint out from the lab! “Enhanced power and transferability for genetics-driven metabolomic biomarker discovery in admixed American cohorts” tackles the important problem that many omics studies still have limited representation of admixed populations www.medrxiv.org/content/10.6...
September 8, 2026 at 8:23 AM
📣 New preprint out from the lab! “Enhanced power and transferability for genetics-driven metabolomic biomarker discovery in admixed American cohorts” tackles the important problem that many omics studies still have limited representation of admixed populations www.medrxiv.org/content/10.6...
Great session at the ASCO/ESMO Joint Session: Biomarker-Driven Therapeutics—Translating Innovation Into Practice. Exciting to see how advances in biomarkers are driving more personalized cancer care. #ASCO25
June 2, 2025 at 7:23 PM
Great session at the ASCO/ESMO Joint Session: Biomarker-Driven Therapeutics—Translating Innovation Into Practice. Exciting to see how advances in biomarkers are driving more personalized cancer care. #ASCO25
Illustration of main ADCs in clinical development for oncogene-addicted #NSCLC. Nice data for both biomarker-agnostic ( anti-TROP2) and biomarker-driven ADCs for various targets and payloads. Drug-to-Ab ratio is depicted by the N of red pins on the Ab surface. @iaslc.bsky.social
#some #lungcancer
#some #lungcancer
November 22, 2024 at 10:29 PM
Illustration of main ADCs in clinical development for oncogene-addicted #NSCLC. Nice data for both biomarker-agnostic ( anti-TROP2) and biomarker-driven ADCs for various targets and payloads. Drug-to-Ab ratio is depicted by the N of red pins on the Ab surface. @iaslc.bsky.social
#some #lungcancer
#some #lungcancer
We will hopefully get to biomarker-driven treatments
But I wonder if we'll also see responsiveness to lower risk & potency meds being used as an indicator that higher potency meds are likely to work...
E.g. more powerful immuno-therapies or nervous system depressants
#MECFS #LongCovid
But I wonder if we'll also see responsiveness to lower risk & potency meds being used as an indicator that higher potency meds are likely to work...
E.g. more powerful immuno-therapies or nervous system depressants
#MECFS #LongCovid
November 30, 2024 at 10:42 PM
We will hopefully get to biomarker-driven treatments
But I wonder if we'll also see responsiveness to lower risk & potency meds being used as an indicator that higher potency meds are likely to work...
E.g. more powerful immuno-therapies or nervous system depressants
#MECFS #LongCovid
But I wonder if we'll also see responsiveness to lower risk & potency meds being used as an indicator that higher potency meds are likely to work...
E.g. more powerful immuno-therapies or nervous system depressants
#MECFS #LongCovid
Important notes:
- the selection of participants was biomarker driven, not a random sample
- whilst improvements were seen in every scoring tool used, that is across all 40 people. We do not yet know how many individuals responded, don’t respond or had intolerable side effects.
- the selection of participants was biomarker driven, not a random sample
- whilst improvements were seen in every scoring tool used, that is across all 40 people. We do not yet know how many individuals responded, don’t respond or had intolerable side effects.
April 4, 2025 at 8:43 AM
Important notes:
- the selection of participants was biomarker driven, not a random sample
- whilst improvements were seen in every scoring tool used, that is across all 40 people. We do not yet know how many individuals responded, don’t respond or had intolerable side effects.
- the selection of participants was biomarker driven, not a random sample
- whilst improvements were seen in every scoring tool used, that is across all 40 people. We do not yet know how many individuals responded, don’t respond or had intolerable side effects.
10/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 1👩⚕️
Therapy options after progression on 1L ET+CDK4/6i are biomarker driven.
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 1👩⚕️
Therapy options after progression on 1L ET+CDK4/6i are biomarker driven.
@dr-rshatsky.bsky.social
January 15, 2025 at 1:31 AM
10/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 1👩⚕️
Therapy options after progression on 1L ET+CDK4/6i are biomarker driven.
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 1👩⚕️
Therapy options after progression on 1L ET+CDK4/6i are biomarker driven.
@dr-rshatsky.bsky.social
Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma @mdanderson.bsky.social #oncology #sarcoma #MedEd www.onclive.com/view/biomark...
Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma
Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.
www.onclive.com
February 18, 2025 at 8:16 PM
Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma @mdanderson.bsky.social #oncology #sarcoma #MedEd www.onclive.com/view/biomark...
Early Detection of Infectious Diseases: A Review of Recent Advances in Pathogen Identification, Molecular Tools, and Metabolomics-Driven Biomarker Discovery pubs.acs.org/doi/10....
---
#proteomics #prot-paper
---
#proteomics #prot-paper
December 27, 2025 at 3:40 PM
Early Detection of Infectious Diseases: A Review of Recent Advances in Pathogen Identification, Molecular Tools, and Metabolomics-Driven Biomarker Discovery pubs.acs.org/doi/10....
---
#proteomics #prot-paper
---
#proteomics #prot-paper
Neue Verwendung für Rapamycin: Bericht über die erste biomarkergestützte Behandlungsstudie bei ME/CFS – Solve ME/CFS Initiative share.google/vW5NR1RAhv2y...
Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS - Solve ME/CFS Initiative
Register today for our free webinar, “Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS,” with the Simmaron Research team. Tues. July 14, @ 3:00 pm PT / 6:00 pm ...
share.google
July 13, 2026 at 8:13 PM
Neue Verwendung für Rapamycin: Bericht über die erste biomarkergestützte Behandlungsstudie bei ME/CFS – Solve ME/CFS Initiative share.google/vW5NR1RAhv2y...
Dr. Janne highlighted therapies for #Lungcancer, how treatment for a biomarker driven cancer increases survival, and how Drug tolerant persisted can lead to resistance to therapy at #NLCRT2024.
December 10, 2024 at 4:06 PM
Dr. Janne highlighted therapies for #Lungcancer, how treatment for a biomarker driven cancer increases survival, and how Drug tolerant persisted can lead to resistance to therapy at #NLCRT2024.
A Review in Nature Reviews Microbiology discusses the role of the #microbiome in cancer development and progression and in treatment response, its potential as a therapeutic target and predictive biomarker, and outlines major knowledge gaps in the field.
go.nature.com/4pOJi5w #medsky 🧪
go.nature.com/4pOJi5w #medsky 🧪
January 21, 2026 at 2:03 PM
A Review in Nature Reviews Microbiology discusses the role of the #microbiome in cancer development and progression and in treatment response, its potential as a therapeutic target and predictive biomarker, and outlines major knowledge gaps in the field.
go.nature.com/4pOJi5w #medsky 🧪
go.nature.com/4pOJi5w #medsky 🧪
Nutrition therapy must evolve into phase-calibrated, biomarker-driven strategy spanning care continuum. Multi-omics + targeted phys rehab provides translational roadmap for improved LT functional recovery & QoL in ICU survivors.
September 14, 2026 at 9:28 AM
Nutrition therapy must evolve into phase-calibrated, biomarker-driven strategy spanning care continuum. Multi-omics + targeted phys rehab provides translational roadmap for improved LT functional recovery & QoL in ICU survivors.
Cancer leads AI physician queries across 9 countries
While cancer continues to be a major global health challenge, it is also a rapidly changing area of medicine. Targeted therapies, immunotherapy, genomic testing, biomarker-driven treatments, and…
While cancer continues to be a major global health challenge, it is also a rapidly changing area of medicine. Targeted therapies, immunotherapy, genomic testing, biomarker-driven treatments, and…
Cancer leads AI physician queries across 9 countries
While cancer continues to be a major global health challenge, it is also a rapidly changing area of medicine. Targeted therapies, immunotherapy, genomic testing, biomarker-driven treatments, and…
news-area.com
September 25, 2026 at 5:59 PM
Cancer leads AI physician queries across 9 countries
While cancer continues to be a major global health challenge, it is also a rapidly changing area of medicine. Targeted therapies, immunotherapy, genomic testing, biomarker-driven treatments, and…
While cancer continues to be a major global health challenge, it is also a rapidly changing area of medicine. Targeted therapies, immunotherapy, genomic testing, biomarker-driven treatments, and…
Great analysis of DLL3 expression in SCLC and difficult to treat neuroendocrine neoplasms. Excited to see more biomarker driven approaches to advance care in such needed spaces.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms - npj Precision Oncology
npj Precision Oncology - Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
www.nature.com
November 20, 2024 at 1:00 AM
Great analysis of DLL3 expression in SCLC and difficult to treat neuroendocrine neoplasms. Excited to see more biomarker driven approaches to advance care in such needed spaces.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Metrodora Institute, PrecisionLife to Launch Biomarker-Driven #LongCOVID, #CFS Trials
www.precisionmedicineonline.com/business-new...
"The organizations will open recruitment for the clinical trials in the US in June with plans to recruit up to 1,000 patients. (contd)”
#MEcfs
1/
www.precisionmedicineonline.com/business-new...
"The organizations will open recruitment for the clinical trials in the US in June with plans to recruit up to 1,000 patients. (contd)”
#MEcfs
1/
Metrodora Institute, PrecisionLife to Launch Biomarker-Driven Long COVID, CFS Trials
The organizations aim to validate genotypic diagnostic tests to identify patient risk and inform appropriate biomarker-targeted treatments.
https://www.precisionmedicineonline.com/business-news/metrodora-institute-precisionlife-launch-biomarker-driven-long-covid-cfs-trials#:~:text=NEW%20YORK%20–%20The%20Metrodora%20Institute,COVID%20that%20the%20organizations%20codeveloped
May 25, 2024 at 12:55 PM
Metrodora Institute, PrecisionLife to Launch Biomarker-Driven #LongCOVID, #CFS Trials
www.precisionmedicineonline.com/business-new...
"The organizations will open recruitment for the clinical trials in the US in June with plans to recruit up to 1,000 patients. (contd)”
#MEcfs
1/
www.precisionmedicineonline.com/business-new...
"The organizations will open recruitment for the clinical trials in the US in June with plans to recruit up to 1,000 patients. (contd)”
#MEcfs
1/
Online Now: Spatial biomarker discovery via interpretable semantic learning in histopathology
Spatial biomarker discovery via interpretable semantic learning in histopathology
Liang et al. introduce PathPrism, a framework that converts whole-slide images into interpretable spatial biomarker spectra, establishing a transparent representation of tissue architecture. This representation enables transparent linear modeling of prognosis, molecular alterations, and treatment response with high performance, while transforming histopathology into a platform for interpretable discovery and perturbation-driven exploration.
dlvr.it
June 18, 2026 at 2:17 PM
Online Now: Spatial biomarker discovery via interpretable semantic learning in histopathology
Do these clinical trial failures demonstrate a failure of traditional pre-clinical models to reflect the human disease?
In addition to the complete avoidance of biomarker-driven clinical trials to find the subset of patients that would benefit.? @asharpmedonc.bsky.social @pcf-science.bsky.social
In addition to the complete avoidance of biomarker-driven clinical trials to find the subset of patients that would benefit.? @asharpmedonc.bsky.social @pcf-science.bsky.social
Dr. Susan Slovin from MSK asks some key questions regarding #ProstateCancer #Immunotherapy
@ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
@ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why?
ascopubs.org
March 17, 2025 at 1:48 PM
Do these clinical trial failures demonstrate a failure of traditional pre-clinical models to reflect the human disease?
In addition to the complete avoidance of biomarker-driven clinical trials to find the subset of patients that would benefit.? @asharpmedonc.bsky.social @pcf-science.bsky.social
In addition to the complete avoidance of biomarker-driven clinical trials to find the subset of patients that would benefit.? @asharpmedonc.bsky.social @pcf-science.bsky.social
Open Access UCL Research: Data-driven mapping of known and novel fluid biomarker progression profiles in genetic frontotemporal lobar degeneration discovery.ucl.ac.uk/id/eprint/10...
Data-driven mapping of known and novel fluid biomarker progression profiles in genetic frontotemporal lobar degeneration
-
UCL Discovery
UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
discovery.ucl.ac.uk
September 24, 2026 at 11:13 AM
Open Access UCL Research: Data-driven mapping of known and novel fluid biomarker progression profiles in genetic frontotemporal lobar degeneration discovery.ucl.ac.uk/id/eprint/10...
Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer's disease https://www.biorxiv.org/content/10.1101/2024.11.23.624811v1
Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer's disease https://www.biorxiv.org/content/10.1101/2024.11.23.624811v1
INTRODUCTION: Changes to the relative abundance of amyloid-beta (Abeta) peptides are hallmarks of Al
www.biorxiv.org
November 23, 2024 at 9:15 PM
Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer's disease https://www.biorxiv.org/content/10.1101/2024.11.23.624811v1